The price that seems too good
The search for an aesthetic treatment in Seoul almost always surfaces a striking range of prices for what appears to be the same procedure. A Juvederm filler injection might be quoted at one clinic for three times the price of another clinic down the same street. Ultherapy packages vary by 50 or 60 percent between providers. Skin boosters are available for what seems like an implausibly low number if you know what the product costs at pharmacy wholesale.
Most international patients — reasonably, intuitively — register this range as an opportunity. Korean aesthetic medicine is already known to be competitive relative to Europe or North America. A clinic offering below-market pricing within that already-competitive market reads as a bargain find.
The thing worth understanding before that conclusion takes hold: in aesthetic medicine, dramatically below-market pricing is not a sign of efficiency. It is a signal that something in the cost structure has been reduced to a point where the economics only work if something else has been substituted. The question is what.
What does an aesthetic treatment actually cost?
Before evaluating any quoted price, it helps to understand what the components of a legitimate treatment cost actually are.
Authentic product cost is often the largest single variable. Genuine imported hyaluronic acid fillers — the major brands manufactured in France, Sweden, or South Korea under full quality controls — carry a fixed wholesale cost that clinics cannot meaningfully discount. A syringe of Juvederm or Restylane costs the clinic a specific amount regardless of volume purchasing. Biorevitalization products like PDRN or polynucleotide injectables have similarly defined costs. When the retail price of a treatment containing these products is significantly below what the product alone costs at legitimate wholesale, something has changed about the product.
Physician fee is the second major component. Physician-led procedures require the time of a licensed physician who trained for years to develop the anatomical understanding and technical precision the procedure requires. That time has a value. In a serious practice, the physician doing the consultation is the same physician doing the procedure — not a physician who reviewed a plan and delegated the injection to a non-physician operator. When pricing is dramatically compressed, physician time is frequently what has been reduced: through delegation, through extreme volume that reduces per-patient time, or through a practice model where a physician is nominally supervising procedures they are not directly performing.
Facility and equipment cost. Operating legitimate clinical equipment — HIFU devices, radiofrequency platforms, laser systems — requires lease payments, maintenance contracts, and periodic calibration. Clinics with genuine equipment at full clinical specification cannot run these below a cost floor. Clinics quoting dramatically low energy treatment prices are often running older devices, unserviced equipment, or machines operating below their nominal parameters.
Anesthesia and comfort. Topical anesthesia, numbing injections, and nerve blocks have a cost in both product and time. Clinics managing volume through speed may apply anesthesia inadequately, which affects both patient experience and the quality of the treatment — a procedure done quickly because the patient is uncomfortable tends to be a procedure done less precisely.
Post-treatment access and follow-up. A properly structured aesthetic treatment includes access to the physician in the days after the procedure if anything requires evaluation. This is not optional in good clinical practice — it is part of the treatment. It requires staff time, physician availability, and a clinical relationship that extends past the invoice.
Complication-rescue capability. This is the cost item patients most often overlook, and the one with the most serious downstream consequences. A clinic prepared to manage complications — vascular occlusion from filler, inflammatory reactions, inadequate results that require correction — maintains hyaluronidase in the procedure room, has trained staff who know emergency protocols, and has established relationships with specialist referral partners for the rare event requiring hospital-level care. As described in Filler Vascular Occlusion Explained, this infrastructure has a cost. A clinic that does not maintain it is not cheaper because of efficiency — it is cheaper because it has eliminated a cost that the patient may eventually need.
What exactly gets cut in a below-market clinic?
The clinical economics leave limited options. When a treatment is priced well below what legitimate cost components allow, the reduction has to come from somewhere specific.
Counterfeit or diverted product is the most consequential cut. The global market for counterfeit aesthetic injectables is substantial and documented in the medical literature. Counterfeit fillers can contain incorrect concentrations of hyaluronic acid, non-sterile formulations, or entirely different materials. Diverted product — genuine brand product sold through unauthorized distribution channels, often stored outside cold-chain conditions — may be technically authentic but compromised in quality. A patient receiving counterfeit or diverted product has no way to know this during the procedure. The difference becomes apparent only through outcome — inadequate results, faster degradation, unexpected inflammatory reactions — or not at all.
Non-physician operator. In many jurisdictions including South Korea, certain injectable procedures require a licensed physician. Some clinics nominally comply with this requirement by having a physician on-site while procedures are performed by nurses or aestheticians under minimal supervision. This is not equivalent to physician-performed treatment. The anatomical judgment that prevents complications — depth of injection, tissue tension, recognition of early vascular compromise — is a clinical skill developed over years of medical training. When pricing reflects non-physician labor costs, it also reflects the removal of that judgment from the room.
No rescue capability. A clinic without hyaluronidase on site, without an emergency protocol, without a physician accessible after hours is a structurally cheaper operation. That lower overhead is passed on as a lower price. The patient who has a late-evening reaction after a procedure and cannot reach anyone is not experiencing a service failure — they are experiencing the clinical consequence of what the price actually meant.
Broker commission absorbed into the price. International patients booking through travel agents, medical tourism platforms, or hotel concierges often receive a quoted price that includes a commission to the referring party — typically 20 to 40 percent of the treatment cost. This is not illegal, but it means the patient is paying the same or more than the clinic’s standard retail price, while the clinic receives significantly less revenue per procedure. In this scenario, the “deal” the broker advertises is not a discount — it is a redistribution of the same money.
The correction cycle and its real cost
There is a pattern we see in consultations with patients who have previously had treatments elsewhere. The original procedure was priced at a significant discount from what a comparable legitimate treatment would cost. The result was either absent, short-lived, or problematic in some way. The patient is now seeking correction, and the correction will cost more than the original legitimate treatment would have.
This pattern has a specific clinical name in the filler literature: the “correction cost” or “revision cost” of suboptimally performed injectable procedures. Depending on the problem — asymmetry, overcorrection, inflammatory granuloma from non-authentic product, skin damage from inadequately calibrated devices — the cost of correction can be two to four times the cost of the original procedure done correctly the first time.
The 30 percent saved on the original treatment does not survive the math of the correction cycle. And this calculation assumes the outcome is correctable. Some complications — tissue damage from non-sterile product, necrosis from unmanaged vascular occlusion, laser burns from uncalibrated devices — are not fully reversible at any price.
This is not a hypothetical concern. The Standards Before Results framework we follow is partly built around the recognition that the standard of care is not a premium add-on — it is what prevents the need for correction in the first place. And Why Lifting Comparisons Mislead Patients describes a parallel pattern in energy treatments: a mismatched device applied to the wrong indication, even with a technically competent operator, produces a wasted result that still needs to be addressed.
How do you read a price quote clearly?
A transparent price quote for an aesthetic treatment is itemized. It tells you: what product will be used (brand, concentration, quantity), what device will be used (model, energy parameters when relevant), who will perform the procedure, and what is included in terms of follow-up and after-hours access.
A quote that is a single number — “filler, one session, X amount” — provides none of this. You cannot evaluate it against comparable options because you do not know what you are comparing. You cannot audit the product cost because you do not know what product is being used. You cannot assess the physician’s involvement because the quote does not specify it.
Requesting itemization is reasonable and, at a legitimate clinic, expected. If itemization is refused or evaded, that is informative.
The other important check is independent product verification. Major filler brands publish the names of their authorized distribution partners and, in some cases, have patient-facing verification systems (QR codes on boxes, certificate numbers) that allow patients to confirm product authenticity before injection. Asking to see the product packaging before the procedure is not an unusual request. A clinic comfortable with that request is comfortable with transparency.
What does a fair price actually reflect?
A treatment priced at what looks like the “premium” end of the market — when the clinic is legitimate — reflects a specific calculation: the physician’s time is paid at a rate that allows them to spend adequate time on the consultation and the procedure; the products used are authentic and within their approved storage and use conditions; the equipment is maintained and calibrated; rescue capability is present; and the patient can reach someone afterward if needed.
This is not a luxury tier. This is the functional minimum for a treatment that works as expected and does not create new problems in the process.
What kind of system are you buying into?
The most useful reframe when evaluating price is this: you are not buying a product. You are buying access to a system — the quality of the physician’s training, the authenticity of the materials used, the safety infrastructure in the room, and the support available after the procedure.
A low price means a different system. Sometimes that system still produces a good outcome. Luck and a patient with straightforward anatomy and no complications can produce a satisfactory result even in a structurally compromised clinical environment. But the margin for error in that environment is smaller, and the consequences of being on the wrong side of that margin are larger.
The more relevant calculation is not “can I get this cheaper elsewhere?” but “what do I need the system to be capable of, and does this price reflect that capability?”
For international patients who are traveling specifically for treatment — and for whom the inconvenience of returning for a correction is more than inconvenient — this question carries additional weight. A complication that a local patient can manage with a follow-up visit becomes a significantly more complex problem for a patient who is leaving the country in 72 hours.
Our pricing is described transparently on the menu page. The design method that governs our protocols is built around the principle that the product is the clinical standard, not the individual device or injectable. The International Patients Guide addresses the practical questions around cost, payment, and what to expect in terms of after-care access specifically for patients visiting from abroad. And for patients who want to understand the Apgujeong market context before arriving, the foreign patient clinic guide provides additional orientation.
The published evidence on complications from counterfeit fillers and below-standard aesthetic procedures is available through PubMed research on counterfeit dermal filler safety complications. It is sobering reading, and it is the clinical literature that informs what minimum clinical standards actually look like.
This article is intended for educational purposes for patients considering aesthetic medicine treatments. It does not constitute a clinical recommendation and does not replace direct physician consultation. Pricing structures described reflect general market patterns; specific pricing for any treatment at Tune Clinic is available through a direct consultation. Contact us with any questions before booking.
